BIOVAXYS AND SPAYVAC-FOR-WILDLIFE, INC. ANNOUNCE LAUNCH OF TRIAL TO TEST IMMUNOCONTRACEPTION IN ASIAN ELEPHANTS

, /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: ) ("BioVaxys") and SpayVac-for-Wildlife, Inc. ("SpayVac") jointly announce that SpayVac has partnered with the Elephant and Wildlife Clinic, Faculty of Veterinary Medicine at Chiang Mai University in to test SpayVac®, a long-lasting, single-dose contraceptive vaccine, in captive Asian elephants.

SpayVac utilizes a patented liposome-based antigen delivery platform technology licensed from BioVaxys ( ) which has demonstrated a robust and sustained immune response in several species. Because free-ranging Asian elephant ( ) populations have become increasingly confined to smaller ranges, concerns grow about human–elephant conflicts and negative impacts on flora and fauna. Current elephant population management alternatives include translocation, dispersal techniques, and contraceptive vaccines.

In a previous trial with captive African elephants ( ), a single-dose of SpayVac raised antibody titers, which remained consistently elevated through at least 7 years. An effective, single-dose vaccine would be a valuable addition to the wildlife manager's toolbox in , , and southeast Asian countries with populations of free-ranging elephants. Initial research trials with Asian elephants began in April and will track reproductive cycling and contraceptive efficacy as well as antibody titers over a 5-year period.

"Elephant population densities have climbed in some areas, even as overall numbers have decreased, pri.